Corbus Pharmaceuticals Reports Q1 2026 Results, Confirms Key Clinical Milestones for CRB-701 & CRB-913

summarizeSummary

Corbus Pharmaceuticals reported Q1 2026 financials and provided key updates on its CRB-701 oncology program, including plans to start a registrational study this summer, and its CRB-913 obesity program, with topline Phase 1b data expected this summer.

check_boxKey Events

• Q1 2026 Financial Results

  The company reported a net loss of $23.0 million for Q1 2026, an increase from $17.0 million in Q1 2025, primarily due to higher clinical development expenses.

• Strong Cash Runway

  Corbus Pharmaceuticals holds $138.2 million in cash, cash equivalents, and investments as of March 31, 2026, which is expected to fund operations into 2028.

• CRB-701 Oncology Program Advances

  The company confirmed broad alignment with the FDA on the registration path for CRB-701 in second-line HNSCC and plans to initiate a registrational study this summer. Updated monotherapy data will be presented at ASCO 2026.

• CRB-913 Obesity Program Nears Data Readout

  Enrollment for the CANYON-1 Phase 1b clinical trial of CRB-913 has been completed, with topline 16-week data from 240 patients anticipated this summer.

auto_awesomeAnalysis

This 8-K provides Q1 2026 financial results, showing an increased net loss but a strong cash position expected to fund operations into 2028. More importantly for a clinical-stage biotech, it offers critical updates on its lead programs: CRB-701 (oncology) is on track to start a registrational study this summer with updated data at ASCO 2026, and CRB-913 (obesity) will report topline Phase 1b data this summer. These timelines provide clear near-term catalysts for investors.